Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Answers to Frequently Asked Questions About Chronic Lymphocytic Leukemia and COVID-19

Jacqueline Barrientos, MD, MS
Nicole Lamanna, MD
John Pagel Headshot
John Pagel, MD, PhD
person default
Jacob D. Soumerai, MD
Released: December 9, 2020
Back Next


  1. Martín‐Moro F, Marquet J, Piris M, et al. Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies. Br J Haematol. 2020;190:e16-e20.
  2. Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:2354-2363.
  3. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134-1143.
  4. American Society of Clinical Oncology. ASCO special report: a guide to cancer care delivery during the COVID-19 pandemic. Available at: https://www.asco.org/sites/new-www.asco.org/files/content-files/2020-ASCO-Guide-Cancer-COVID19.pdf. Accessed November 17, 2020.
  5. Johns Hopkins University Medicine Coronavirus Resource Center. COVID-19 United States cases by county. Available at: https://coronavirus.jhu.edu/us-map. Accessed November 17, 2020.
  6. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.
  7. American Society of Hematology. ASH guidelines on use of anticoagulation in patients with COVID-19. Available at: https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19. Accessed November 17, 2020.
  8. de Simone G, Mancusi C. COVID-19: timing is important. Eur J Intern Med. 2020;77:134-135.
  9. Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047-3049.
  10. van der Velden AMT, Mulder AHL, Hartkamp A, et al. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med. 2001;12:420-424.
  11. Sun C, Gao J, Couzens L, et al. Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncol. 2016;2:1656-1657.
  12. Svensson T, Kättström M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia: a randomized study by the Swedish CLL group. Vaccine. 2018;36:3701-3707.
  13. Centers for Disease Control and Prevention. Fluzone high-dose seasonal influenza vaccine. Available at: https://www.cdc.gov/flu/prevent/qa_fluzone.htm. Accessed November 17, 2020.
  14. Ma S, Platanias LC. Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia? Expert Opin Pharmacother. 2018;19:1171-1175.
  15. ClinicalTrials.gov. Testing the effects of early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab for newly diagnosed patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma who do not have symptoms, the EVOLVE CLL/SLL Study. Available at: https://clinicaltrials.gov/ct2/show/NCT04269902. Accessed November 17, 2020.
  16. ClinicalTrials.gov. Study to investigate the use of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia. Available at: https://clinicaltrials.gov/ct2/show/NCT04178798. Accessed November 17, 2020.
  17. Venetoclax [package insert]. North Chicago, IL: AbbVie Inc.; 2020.
  18. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134-1143.
  19. Acalabrutinib [package insert]. Redwood City, CA: Acerta Pharma B.V.; 2019.
  20. Ibrutinib [package insert]. Sunnyvale, CA: Pharmacyclics LLC; 2020.
  21. Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5:eabd0110.
  22. Alsuliman T, Belghoul M, Choufi B. Ibrutinib treatment through nasogastric tube in a comatose patient with central nervous system localization of mantle cell lymphoma. Case Rep Hematol. 2018;2018:5761627.
  23. Maddox JM, Majid M. Use of ibrutinib via nasogastric (NG) tube & percutaneous endoscopic gastrostomy (PEG) tube. Program and abstracts of the 2016 American Society of Hematology Annual Meeting; December 3-6, 2016; San Diego, California. Abstract 5371.
  24. Rattanawong P, Shen W, Hicham El Masry H, et al. Guidance on short-term management of atrial fibrillation in coronavirus disease 2019. J Am Heart Assoc. 2020;9:e017529.
  25. Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135:1912-1915.
  26. Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019;30 Suppl 10:x21-x26.
Back Next
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings